YZi Labs announces investment in regenerative medicine company Renewal Bio

According to official news, YZi Labs announced an investment in the regenerative medicine company Renewal Bio, marking YZi Labs' first biotechnology investment since expanding its investment scope in early 2025.

Renewal Bio focuses on utilizing its proprietary Stembroid™ platform to generate human cells and tissues that are DNA-matched to the patient from the patient's own cells, aiming to address the global organ shortage crisis. Over 150,000 organ transplants are performed worldwide each year, yet less than 10% of the demand is met. Renewal Bio reprograms ordinary skin or blood cells into stem cells by simulating the early human developmental environment, generating various functional cells, including hematopoietic, liver, heart, and pancreatic cells.

The company was co-founded in 2022 by Professor Jacob Hanna from the Weizmann Institute of Science and his two PhD students, Vladislav Krupalnik and Ohad Gafni. This round of financing will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for the treatment of leukemia and immune diseases, and support the expansion of laboratory infrastructure.